The Filing Desk

Autolus Therapeutics vs Cellectis

Autolus Therapeutics AUTL · Cellectis CLLS · Biotechnology

Autolus Therapeutics reported revenue of $75 million in fiscal 2025, about the same as Cellectis' $73 million in fiscal 2025. Autolus Therapeutics' revenue grew 644.9% in its latest year, and Cellectis' grew 75.8%. Autolus Therapeutics had an operating margin of -358.9%, against -45.3% at Cellectis. Free cash flow was −$303 million at Autolus Therapeutics and −$42 million at Cellectis.

Side by side

Autolus TherapeuticsCellectis
Latest fiscal yearFY2025, Dec 31, 2025FY2025, Dec 31, 2025
Revenue$75M$73M
Revenue growth644.9%75.8%
Revenue growth a year, last 5 years—7.4%
Gross margin−27.8%100.0%
Operating margin−358.9%−45.3%
Net margin−381.4%−92.7%
Free cash flow−$303M−$42M
Free cash flow margin−401.4%−57.2%
Return on capital——
Net debt to EBITDA——
Dividends and buybacks$0M$0M
Change in diluted share count4.3%10.7%
Last close$0.98$0.98
P/E at the last close——
Insider trades, last 12 monthssold $15,708—
Piotroski F-score3 of 9—
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.

Ten years

Revenue
US$ billions, fiscal years
Autolus TherapeuticsCellectis
Operating margin
Percent of revenue
Autolus TherapeuticsCellectis
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
Autolus TherapeuticsCellectis

Start a new comparison

Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Autolus Therapeutics and Cellectis pages.